Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1477 • ACR Convergence 2020
Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
Patricia Castro Pérez¹, Alberto Onteniente González¹, Angel Aragón Díez¹, Angel Gallegos Cid¹, Jesús Garcia-Arroba Muñoz¹ and Jose Manuel Rodriguez heredia¹, ¹Hospital de Getafe, Madrid, Spain
Background/Purpose: Adherence to treatments for chronic rheumatic diseases is influenced by many factors, including the patient's belief in the development of adverse effects such as…
Abstract Number: 1551 • ACR Convergence 2020
Rapid Effect of Tofacitinib in Reducing US Joint and Tendon Inflammatory Lesions of RA Patients: Data from a 24 Weeks Longitudinal Study
Giuseppe Germanò¹, Pierluigi Macchioni², Giovanni Ciancio³, Filippo Crescentini¹, Andrea Caruso², Beatrice Maranini⁴, Sara Bonazza⁴, Gilda Sandri⁵, Maria Teresa Mascia⁵, Govoni Marcello⁴ and Carlo Salvarani⁶, ¹Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, REGGIO NELL'EMILIA, Emilia-Romagna, Italy, ²Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, REGGIO NELL'EMILIA, Italy, ³Unità Operativa Complessa di Reumatologia Azienda Ospedaliero-Universitaria S. Anna -Ferrara, Ferrara, Emilia-Romagna, Italy, ⁴Unità Operativa Complessa di Reumatologia Azienda Ospedaliero-Universitaria S. Anna -Ferrara, Ferrara, Italy, ⁵Struttura Complessa di Reumatologia- Università di Modena e Reggio Emilia- Policlinico di Modena, Modena, Italy, ⁶Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: To explore the effects of tofacitinib (Tofa) on US lesions in a consecutive series of patients with active RA MTX and/or bioDMARDs -IR. Methods: In…
Abstract Number: 1707 • ACR Convergence 2020
Development and Delivery of Continuing Education Interventions Promoting Shared Decision Making in Rheumatoid Arthritis
Richard Martin¹, Marianna Shershneva² and Lily Zurkovsky³, ¹Michigan State University College of Human Medicine, Grand Rapids, MI, ²Senior Administrative Program Specialist, Office of Continuing Professional Development University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Forefront Collaborative, Carmel, IN
Background/Purpose: A core CMS policy goal is to improve patient experience by encouraging patient-centered care and shared decision making (SDM). However, SDM techniques are underutilized…
Abstract Number: 1728 • ACR Convergence 2020
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Martin Bergman¹, Jeffrey Enejosa², Naomi Martin², Jessica Suboticki², Debbie Goldschmidt³, Yan Song³ and Namita Tundia², ¹Drexel University College of Medicine, Philadelphia, PA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA
Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…
Abstract Number: 1745 • ACR Convergence 2020
A Novel Method for Predicting 1-Year Retention of Abatacept Using Machine Learning Techniques
Rieke Alten¹, Claire Behar², Christine Boileau², Pierre Merckaert², Ebenezer Afari², Virginie Vannier-Moreau³, Sean Connolly³, Yedid Elbez², Pierre-Antoine Juge⁴ and Karissa Lozenski³, ¹Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ²Excelya, Boulogne-Billancourt, France, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
Background/Purpose: In the ACTION (NCT02109666) study, using multivariable Cox proportional hazards regression models, patient (pt) global assessment of pain, country, reason for stopping last biologic,…
Abstract Number: 1762 • ACR Convergence 2020
Benefit and Risk Profiles of Janus Kinase Inhibitors Approved in the US for the Treatment of RA
Alvin Wells¹, Kirstin Griffing², Amanda Quebe², Luna Sun², Hong Zhang³ and Paulo Reis², ¹Aurora Rheumatology and Immunotherapy Center, Franklin, ²Eli Lilly and Company, Indianapolis, IN, ³Tech Data Services, King of Prussia, PA
Background/Purpose: In clinical practice, drug treatment decisions must account for the expected benefit from a drug along with its potential risks. Evaluating the number needed…
Abstract Number: 1970 • ACR Convergence 2020
Mimicking Cytokine-driven Key Features of Arthritis Using a Human in Vitro 3D Joint Model
Alexandra Damerau¹, Moritz Pfeiffenberger¹, Annemarie Lang¹, Timo Gaber¹ and Frank Buttgereit², ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine, Berlin, Germany
Background/Purpose: Our ultimate goal is to study potential drug candidates in an experimental setting of arthritis. Therefore, we aim to develop a human in vitro…
Abstract Number: 2005 • ACR Convergence 2020
Histo-pathological Cellular Markers of Treatment Response to Rituximab and Tocilizumab in Matched Pre- and Post-treatment Synovial Biopsies from the R4RA Randomised Clinical Trial in Rheumatoid Arthritis
Felice Rivellese¹, Frances Humby², Giovanni Giorli², Alessandra Nerviani¹, Rebecca Hands², Liliane Fossati-Jimack², Georgina Thorborn², Myles Lewis¹ and Costantino Pitzalis², ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom
Background/Purpose: The results of the R4RA trial, the first biopsy-based RCT in TNF-i inadequate responders patients with Rheumatoid Arthritis (RA), showed that molecular stratification of…
Abstract Number: 0025 • ACR Convergence 2020
Clinical and Psychological Assessment of Rheumatoid Arthritis Patients with Fibromyalgia: A Real World Study
Tian Liu¹, Chao Gao¹ and Lihong Chen¹, ¹hospital, Beijing, China (People's Republic)
Background/Purpose: To assess the clinical features and psychological status of the rheumatoid arthritis(RA) patients with fibromyalgia(FM) in a real-world observational setting.Methods: Between December 2018 to…
Abstract Number: 0081 • ACR Convergence 2020
Prevalence of Systemic Autoimmune Diseases in Polycystic Ovary Syndrome
Saika Sharmeen¹, Hafsa Nomani², Erin Taub³ and Qingping Yao³, ¹Stony Brook University Renaissance School of Medicine, Dix Hills, NY, ²Stony Brook University Renaissance School of Medicine, West Babylon, NY, ³Stony Brook University Renaissance School of Medicine, Stony Brook, NY
Background/Purpose: Polycystic ovary syndrome (PCOS) is characterized by hormonal abnormality, chronic anovulation, hyperandrogenism, and obesity. Due to the hormonal imbalance, we hypothesize that patients with…
Abstract Number: 0146 • ACR Convergence 2020
Patients’ Perceptions and Expectations Towards the Role of Rheumatologists in the Recommendations of Physical Activity’s Practice – A Cross-sectional Study Involving 308 Patients Living with Rheumatoid Arthritis in France
Anne-Christine Rat¹, Arnaud Constantin², Catherine Beauvais³, Yannick Guillodo⁴, Valérie Guay⁵, Emilie Pain⁶, Alexis Bombezin--Domino⁶ and Florence E Lévy Weil⁷, ¹Universite de Caen Normandie and Université de Lorraine, EA 4360, Caen, France, ²Hospital Pierre Paul Riquet, Toulouse, France, ³Saint-Antoine Hospital, AP-HP, Rheumatology Department, Sorbonne-Université, Paris, France, Paris, France, ⁴La Cavale Blanche University Hospital, Rheumatology Department, Brest, France, Brest, France, ⁵Argenteuil Hospital, Physiotherapist, Health executive, Argenteuil, France, Argenteuil, France, ⁶Carenity, Online Patient Community, Paris, France, Paris, France, ⁷Sanofi Genzyme, Gentilly, France, Gentilly, France
Background/Purpose: Rheumatologists consider physical activity (PA) to be an important goal in the care for patients with rheumatoid arthritis (RA). However, there are very few…
Abstract Number: 0183 • ACR Convergence 2020
Incidence of Malignancies in Japanese Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry
Toshihiro Matsui¹, Naonobu Sugiyama², Tsutomu Kawaguchi², Aosa Kamezaki², Shigeyuki Toyoizumi³, Fujio Matsuyama⁴, Tatsunori Murata⁴, Yukitomo Urata⁵, Kimito Kawahata⁶ and Shigeto Tohma⁷, ¹Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan, ²Pfizer Japan Inc, Tokyo, Japan, ³Pfizer R&D Japan G.K., Tokyo, Japan, ⁴CRECON Medical Assessment Inc, Tokyo, Japan, ⁵Department of Rheumatology, Tsugaru General Hospital, Aomori, Japan, ⁶Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁷National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: Patients (pts) with RA have an increased risk of some malignancies compared with the general population, and this can vary by region/race.1,2 Epidemiologic data…
Abstract Number: 0200 • ACR Convergence 2020
Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study
Kunihiro Yamaoka¹, Stanley B Cohen², Naonobu Sugiyama³, Harry Shi⁴, Jose L Rivas⁵, Annette Diehl⁴ and Josef Smolen⁶, ¹Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ²Metroplex Clinical Research Center, Dallas, TX, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer SLU, Madrid, Spain, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: ORAL Shift, a global Phase 3b/4 non-inferiority study, demonstrated sustained efficacy/safety of tofacitinib modified-release (MR) 11 mg QD following MTX withdrawal in patients (pts)…
Abstract Number: 0216 • ACR Convergence 2020
A Subgroup Analysis of Low Disease Activity and Remission from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Jacques-Eric Gottenberg¹, Maya Buch², Roberto Caporali³, Grace Wright⁴, Tsutomu Takeuchi⁵, Kenneth Kalunian⁶, Alena Pechonkina⁷, Ying Guo⁷, Shangbang Rao⁸, YingMeei Tan⁸, Robin Besuyen⁹ and Mark Genovese¹⁰, ¹Strasbourg University Hospital, Strasbourg, France, ²Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ³Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁴Association of Women in Rheumatology, New York, NY, ⁵Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁶School of Health Sciences, University of California, La Jolla, ⁷Gilead Sciences, Inc., Foster City, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Galapagos BV, Leiden, Netherlands, ¹⁰Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Despite effective treatments, many patients (pts) with rheumatoid arthritis (RA) have inadequate responses to biologic DMARDs (bDMARD-IR), highlighting an unmet need. It is unclear…
Abstract Number: 0233 • ACR Convergence 2020
Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients
C. Fernandez-Diaz¹, Santos Castañeda², Rafael Melero³, Francisco Miguel Ortiz Sanjuan⁴, Antonio Juan-Mas⁵, Carmen Carrasco Cubero⁶, Raquel Almodovar⁷, Sebastian Rodriguez-Garcia⁸, C. Aguilera-Cros⁹, Ignacio Villa¹⁰, S. Ordoñez¹¹, Enrique Raya¹², C. Ojeda¹³, Manuel Jose Moreno-Ramos¹⁴, Gema Bonilla¹⁵, Susana Romero-Yuste¹⁶, Ana Ruibal-Escribano¹⁷, Jose Luis Andreu Sanchez¹⁸, R. Exposito¹⁹, Javier Loricera²⁰, Natalia Mena-Vazquez²¹, Ana Urriticoechea²², C. Peralta²³, Luis Arboleya²⁴, Francisco Javier Narváez²⁵, O. Maiz²⁶, Julia Fernandez Melon²⁷, P Vela²⁸, Ivan Castellvi²⁹, I. Cabezas³⁰, Alejandra Lopez Robles³¹, Patricia Carreira Delgado³², Juan M. Blanco-Madrigal³³, N. Del-val-del-amo³⁴, E Salgado³⁵, B. Garcia-magallon³⁶, Cristina Hidalgo Calleja³⁷, Mireia Corbeto Lopez³⁸, A. Perez³⁹, S. Castro⁴⁰, Juan Ramón De dios⁴¹, Andrea García Valle⁴², R Lopez⁴³, Angel García Aparicio⁴⁴, EC Cervantes⁴⁵, C Gonzalez⁴⁶, N Alvarez-Rivas⁴⁷, L. Perez⁴⁸, Miguel Ángel González-Gay⁴⁹ and Ricardo Blanco⁵⁰, ¹H. Marqués de Valdecilla, Madrid, Spain, ²Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³CHU. VIgo, Vigo, Spain, ⁴Rheumatology Department, HUP La Fe, Valencia, Spain, ⁵Son Llàzer University Hospital, Mallorca, Spain, ⁶H. Mérida, Mérida, Spain, ⁷Fundación Alcorcón University Hospital, Madrid, ⁸La Princesa University Hospital, Madrid, Spain, ⁹H.Virgen del Rocio, Sevilla, Spain, ¹⁰H. Torrelavega, Santander, Spain, ¹¹H. Arnau Vilanova, LLeida, Spain, ¹²San Cecilio Clinic Universitary Hospital, Granada, Spain, ¹³H. Virgen de la Macarena, Sevilla, Spain, ¹⁴Arrixaca University Hospital, Murcia, ¹⁵Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ¹⁶H Pontevedra, Coruna, Spain, ¹⁷Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ¹⁸Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹⁹H. Laredo, Laredo, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Hospital Regional Universitario de Málaga, Málaga, Spain, ²²Can Misses, Ibiza, Spain, ²³H. Clinico Zaragoza, Zaragoza, Spain, ²⁴H. Oviedo, Oviedo, Spain, ²⁵Hospital Bellvitge, BARCELONA, Spain, ²⁶H. Donosti, Donosti, Spain, ²⁷H. Son Espases, Mallorca, Spain, ²⁸H Alicante, Alicante, Spain, ²⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ³⁰H. Río Ortega, Valladolid, Spain, ³¹H. León, León, ³²H. 12 de octubre, Madrid, Spain, ³³Basurto University Hospital, Bilbao, Spain, ³⁴Complejo Hospitalario de Navarra, Pamplona, Spain, ³⁵CHU Ourense, Ourense, Spain, ³⁶H. Huesca, Zaragoza, Spain, ³⁷Hospital Universitario Salamanca, Salamanca, Spain, ³⁸Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, ³⁹H. Puerta del Mar, Cadiz, Spain, ⁴⁰H. Joan XXIII, Tarragona, Spain, ⁴¹H. Alava, Alava, Spain, ⁴²H. Palencia, Palencia, Spain, ⁴³H. Negrin, Las Palmas, Spain, ⁴⁴H. Mostoles, Madrid, Spain, ⁴⁵H. Santiago de compostela, Santiago, Spain, ⁴⁶H. Valladolid, Valladolid, Spain, ⁴⁷H. S Agustin, Aviles, Spain, ⁴⁸Hospital Universitario Virgen de las Nieves, Granada, Spain, ⁴⁹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵⁰Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: To assess the efficacy of abatacept (ABA) in Rheumatoid Arthritis (RA) patients with Interstitial Lung Disease (ILD) (RA-ILD).Methods: Observational multicenter study of RA-ILD patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].